EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi Deutschland GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• IDACIO (ADALIMUMAB-AACF)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 02/07/2026